Anavex Life Sciences (AVXL) Net Income (2016 - 2025)
Anavex Life Sciences recorded quarterly Net Income of -$5.7 million in Q4 2025, up 47.61% quarter-over-quarter from -$10.8 million in Q3 2025, and up 58.2% year-over-year from -$3.6 million in Q4 2024.
Anavex Life Sciences' Net Income history runs 10 years deep, the most recent figure standing at -$5.7 million for Q4 2025.
- In Q4 2025, Net Income rose 58.2% year-over-year to -$5.7 million; the TTM figure through Dec 2025 stood at -$43.5 million (up 9.56% YoY), while the FY2025 annual figure was -$51.4 million, down 19.55% from the prior year.
- Net Income came in at -$5.7 million for Q4 2025 at Anavex Life Sciences, up from -$10.8 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$5.7 million in Q4 2025 to a low of -$14.5 million in Q2 2025.
- A 5-year average of -$11.3 million and a median of -$11.5 million in 2021 frame the typical range for Net Income.
- Across the five-year window, Net Income plunged 96.45% in 2021 and surged 58.2% in 2025, its largest moves.
- Anavex Life Sciences' Net Income stood at -$10.9 million in 2021, then fell by 19.2% to -$13.0 million in 2022, then jumped by 33.53% to -$8.6 million in 2023, then tumbled by 57.64% to -$13.6 million in 2024, then soared by 58.2% to -$5.7 million in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$5.7 million, -$10.8 million, and -$14.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | -5.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.68 Mn |
| Sep 30, 2025 | -10.84 Mn |
| Jun 30, 2025 | -14.46 Mn |
| Mar 31, 2025 | -12.51 Mn |
| Dec 31, 2024 | -13.59 Mn |
| Sep 30, 2024 | -11.74 Mn |
| Jun 30, 2024 | -12.21 Mn |
| Mar 31, 2024 | -10.55 Mn |
| Dec 31, 2023 | -8.62 Mn |
| Sep 30, 2023 | -10.15 Mn |
| Jun 30, 2023 | -11.28 Mn |
| Mar 31, 2023 | -13.11 Mn |
| Dec 31, 2022 | -12.97 Mn |
| Sep 30, 2022 | -14.29 Mn |
| Jun 30, 2022 | -12.37 Mn |
| Mar 31, 2022 | -10.44 Mn |
| Dec 31, 2021 | -10.88 Mn |
| Sep 30, 2021 | -11.72 Mn |
| Jun 30, 2021 | -10.18 Mn |
| Mar 31, 2021 | -8.16 Mn |
| Dec 31, 2020 | -7.86 Mn |
| Sep 30, 2020 | -5.97 Mn |
| Jun 30, 2020 | -6.49 Mn |
| Mar 31, 2020 | -7.24 Mn |
| Dec 31, 2019 | -6.59 Mn |
| Sep 30, 2019 | -5.61 Mn |
| Jun 30, 2019 | -6.52 Mn |
| Mar 31, 2019 | -7.25 Mn |
| Dec 31, 2018 | -6.92 Mn |
| Sep 30, 2018 | -5.59 Mn |
| Jun 30, 2018 | -2.85 Mn |
| Mar 31, 2018 | -4.75 Mn |
| Dec 31, 2017 | -4.06 Mn |
| Sep 30, 2017 | -5.15 Mn |
| Jun 30, 2017 | -3.61 Mn |
| Mar 31, 2017 | -1.55 Mn |
| Dec 31, 2016 | -3.15 Mn |
| Sep 30, 2016 | -6.51 Mn |
| Jun 30, 2016 | -2.24 Mn |